Safety Analysis of Bevacizumab-Containing Adjuvant Chemotherapy in a Phase II Pilot Trial
The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in breast cancer. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for breast cancer.

**Learning Objective**

- Recall the early safety findings with adjuvant docetaxel, cyclophosphamide and bevacizumab in the management of HER2-normal early-stage breast cancer.

**Accreditation Statement**

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Designation Statement**

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**How to Use This CME Activity**

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

**Content Validation and Disclosures**

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**Faculty**

- William J Gradishar, MD
  - Director, Breast Medical Oncology
  - Professor of Medicine
  - Robert H Lurie Comprehensive Cancer Center
  - Northwestern University Feinberg School of Medicine
  - Chicago, Illinois

**Advisory Committee**


**Editor**

- Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests:

**Company**


**Research to Practice Staff and External Reviewers**

- The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

**Last Review Date**

- March 2011

**Expiration Date**

- March 2012
Click here for SABCS papers on HER2-negative breast cancer

In 2001 the first results from the ATAC trial demonstrated the superiority of an AI (anastrozole) over tamoxifen. One year later a CALGB study showed an advantage for dose-dense AC→paclitaxel, and not long after that US Oncology proved that TC was better than AC and along the way the NSABP presented data on the Oncotype DX® assay to help select patients for adjuvant chemo. However, since the presentation of those important yet modest research advances, one could make the argument that not a whole lot else positive has happened in adjuvant treatment for the 80 percent of patients with HER2-negative breast cancer.

2010 didn’t do much to change this situation — at least that’s my conclusion after watching Alan Coates’ San Antonio “Year in Review” presentation on the management of early breast cancer. Of the 18 papers he discussed during this talk, none seem likely to lead to a meaningful change in the mortality of this disease. Perhaps the most provocative of the bunch highlighted by Dr Coates were the three neoadjuvant HER2-positive papers reviewed in a previous issue of this series. However, the HER2-negative papers that were “featured” made me long for a myeloma-like infusion of new agents that actually work.

Unfortunately, it’s not totally clear that this is on the horizon, especially if the data sets coming out in San Antonio are any indication. What we saw there were mainly a few legacy studies evaluating adjuvant chemotherapy, including:

1. Findings from another CALGB trial suggesting similar outcomes with four and six cycles of dose-dense paclitaxel or AC.

2. Two trials testing the addition of capecitabine to anthracycline/taxane regimens demonstrating questionable or no benefit, although two other related data sets suggested a slightly greater advantage with cape in triple-negative disease.

3. Early tolerability data on “maintenance” capecitabine after an anthracycline and/or a taxane — a strategy that makes sense, but no definitive efficacy data exist yet.

4. Another early safety report in a trial evaluating bevacizumab/chemotherapy in the adjuvant setting, but the recent negative results of two adjuvant trials of bev in colon cancer have perhaps dampened enthusiasm for this approach.
It’s a real disconnect to walk through the halls of San Antonio and see thousands of investigators presenting a seemingly endless array of data sets and still contemplate the fact that the current overall impact of this effort at a patient care level — especially in the most prevalent HER2-negative breast cancer subset — is relatively modest. It makes one wonder if we will soon see the payoff of this extensive investment in research and whether there is any way to change the trajectory of progress.

Next up on our final San Antonio issue of *5-Minute Journal Club*: Clinical trials in metastatic disease, including studies of combinations of biologic agents

Neil Love, MD
Research To Practice
Miami, FL
Safety Analysis of Bevacizumab-Containing Adjuvant Chemotherapy in a Phase II Pilot Trial

Presentation discussed in this issue

Crown J et al. Bevacizumab (Bev) in combination with docetaxel (T) and cyclophosphamide (C) as adjuvant treatment (AdjRx) for patients (pts) with early stage (ES) breast cancer (BrCa) and normal HER-2 status. A pilot evaluation. San Antonio Breast Cancer Symposium 2010; Abstract P5-10-17.

Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with William J Gradishar, MD (1/4/11)

Bevacizumab (Bev) in Combination with Docetaxel (T) and Cyclophosphamide (C) as Adjuvant Treatment (AdjRx) for Patients (Pts) with Early Stage (ES) Breast Cancer (BrCa) and Normal HER-2 Status. A Pilot Evaluation

Methods

**Accrual** = 106 (Closed)

**Eligibility**
- Early-stage breast cancer (ESBC)
- HER2-normal
- Node-positive, or >2 cm and receptor-negative, or >3 cm and receptor-positive
- Normal cardiac ejection fraction

Patients were monitored clinically, with blood pressure (BP) measurements before each bevacizumab infusion, regular echocardiograms and serial estimations of B-type natriuretic peptide (BNP) and troponin.

1 75 mg/m² day 1 q3wk x 4
2 600 mg/m² day 1 q3wk x 4
3 15 mg/kg day 1 q3wk x 18

Crown J et al. *Proc SABCS* 2010;Abstract P5-10-17; ClinicalTrials.gov Identifier NCT00911716.

Patient Disposition

<table>
<thead>
<tr>
<th>TC + Bev (n = 106)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy completion (all phases)</td>
</tr>
<tr>
<td>Still on treatment</td>
</tr>
<tr>
<td>Removal from study</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Intestinal perforation</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

## Select Serious Adverse Events (SAEs)*

<table>
<thead>
<tr>
<th>n (%)</th>
<th>TC + Bev</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAEs (all types, any grade)†</td>
<td>21 (19.8%)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>5 (4.7%)</td>
</tr>
<tr>
<td>Neutropenic sepsis</td>
<td>3 (2.8%)</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>3 (2.8%)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>2 (1.9%)</td>
</tr>
<tr>
<td>GI perforation</td>
<td>2 (1.9%)</td>
</tr>
</tbody>
</table>

* Occurring in >1% of patients on study

† 34 SAEs (31 involved hospital admissions, 3 were serious for other reasons) occurred on study in these 21 patients


## Hypertension and Cardiac Toxicity

<table>
<thead>
<tr>
<th>Hypertension (HTN)</th>
<th>TC + Bev (n = 106)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN (while on study)</td>
<td>41 (39.8%)</td>
</tr>
<tr>
<td>HTN (requiring antihypertensives)</td>
<td>35 (85.4%)</td>
</tr>
<tr>
<td>Time to onset of hypertension (median)</td>
<td>154 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiac toxicity; median ejection fraction (EF) at baseline = 67%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drop in EF of 10-15% from baseline</td>
</tr>
<tr>
<td>Drop in EF of 15-20% from baseline</td>
</tr>
<tr>
<td>Drop in EF of &gt;20% from baseline</td>
</tr>
<tr>
<td>Drop in EF to &lt;50%</td>
</tr>
</tbody>
</table>

No cases of congestive heart failure observed. Serial estimations of BNP and troponin indicated no significant changes throughout the study treatment.

Author Conclusions

- The spectrum and frequency of bevacizumab toxicity in this study were similar to those reported for patients with metastatic breast cancer and other types of cancer.
- Hypertension was the principal cause of treatment discontinuation, but cardiac toxicity appeared to be limited.
- Intestinal perforation can also occur in patients with ESBC even without history of previous abdominal surgery or intestinal chronic diseases.
- These toxicities can occur in the post-chemotherapy phase of bevacizumab therapy.
- Patients enrolled on randomized trials of bevacizumab-containing adjuvant therapy require careful monitoring for toxicity.


Investigator Commentary: Safety of Bevacizumab in Combination with Docetaxel/Cyclophosphamide in the Adjuvant Setting

This pilot study by Crown and colleagues was a small, single-arm clinical trial with approximately 100 patients. They demonstrated that it was feasible to administer bevacizumab with adjuvant docetaxel and cyclophosphamide. No surprises were observed with respect to side effects.

Some hypertension occurred, which is predictable, but no significant cardiac signal was observed. Obviously, we cannot make any comments whatsoever about efficacy, so the key data will come from the large, ongoing trials evaluating bevacizumab in the adjuvant setting.

Interview with William J Gradishar, MD, January 4, 2011